Breaking: Helus’ Deuterated Psilocin Hits Primary Endpoint in First Phase 3
- Trial Design
- Efficacy
- Safety
- Competitive Positioning
This morning, Helus Pharma (formerly Cybin) announced a positive topline readout from its first Phase 3 study of HLP003, a deuterated psilocin analog, for the adjunctive treatment of major depressive disorder (MDD).
Here, we provide breaking coverage and rapid analysis.
Trial Design
Helus’ Phase 3 program, PARADIGM, trials HLP003 as an adjunctive treatment for MDD in adults who have had an inadequate response to antidepressants.
It features two pivotal studies: APPROACH, which read out this morning, and EMBRACE, which continues to enrol, with topline results expected in Q4 2027. In APPROACH, participants received two doses of 16 mg HLP003 or placebo, three weeks apart.
Some participants are also followed in a long-term extension study, EXTEND, which features open-label dosing or re-dosing for participants who did not respond or who relapsed, and is expected to complete in 2028...
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks